Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2014 Q2- Text added to 2014 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
addressed, affiliate, AMP, Auckland, biopharmaceutical, brand, branded, Budget, build, committed, complement, conclusion, Congressional, deficit, EGFR, epidermal, factor, gap, Hypoxin, HypoxinTM, implanted, infused, inhaled, injected, instilled, intent, irreversible, issuer, licensor, Likewise, methodology, mice, minimum, Obama, originally, outpatient, owed, pipeline, plasma, prematurely, rationale, rebate, receptor, region, release, Relief, subset, Taxpayer, thereof, thereunder, translational, trillion, University, usable, xenograft
Removed:
EPA
Valuein 2014 Q2 filing- Value in 2014 Q3 filing
Original filings
Filing view